share_log

Earnings Call Summary | RECKITT BENCKISER GROUP PLC(RBGPF.US) Q4 2023 Earnings Conference

Earnings Call Summary | RECKITT BENCKISER GROUP PLC(RBGPF.US) Q4 2023 Earnings Conference

業績電話會議摘要 | RECKITT BENCKISER GROUP PLC (RBGPF.US) 2023 年第四季度業績發佈會
富途資訊 ·  03/01 17:25  · 電話會議

The following is a summary of the Reckitt Benckiser Group Plc (RBGPF) Q4 2023 Earnings Call Transcript:

以下是Reckitt Benckiser Group Plc(RBGPF)2023年第四季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Reckitt Benckiser witnessed a progressive 2023 with net revenue growth surpassing expectations, despite a small setback due to a discrepancy in the Middle East markets.

  • Gross margins improved to 60%, helping to underpin increased brand and innovation investments.

  • A year-end adjusted operating profit of £3.373 billion was reported, despite a minor decrease in adjusted diluted earnings per share (down by 5.4%).

  • The company saw an 11% highest on record surge in free cash flows, achieving £2.258 billion.

  • The company returned a resonating £1.5 billion to shareholders through dividends and share buybacks.

  • Reckitt Benckiser見證了2023年的進步,儘管由於中東市場的差異而遭受了小幅挫折,但淨收入增長超出了預期。

  • 毛利率提高到60%,這有助於支撐品牌和創新投資的增加。

  • 儘管調整後的攤薄後每股收益略有下降(下降5.4%),但年終調整後的營業利潤爲33.73億英鎊。

  • 該公司的自由現金流創歷史新高11%,達到22.58億英鎊。

  • 該公司通過分紅和股票回購向股東返還了15億英鎊。

Business Progress:

業務進展:

  • Reckitt Benckiser's health and hygiene divisions delivered mid-single-digit growth, a trend it expects to sustain through 2024.

  • A fixed cost optimization program was launched and is anticipated to support future growth.

  • Compliance issues in two Middle Eastern markets and a voluntary product recall in the Nutrition business were immediately addressed.

  • The firm plans to continue investing in product quality, branding, and executing its strategies consistently.

  • The company emphasized their commitment to dividend growth and are expected to continue their share buyback actions.

  • Growth plans for 2024 include high-to-mid single-digit decline in Nutrition with a return to growth by year-end, an increase in capex range to 3-3.5%, and like-for-like net revenue growth of 2-4%.

  • A strong free cash flow is expected to be delivered in 2024, allowing for additional returns to shareholders.

  • Reckitt Benckiser的健康和衛生部門實現了中等個位數的增長,預計這一趨勢將持續到2024年。

  • 固定成本優化計劃已經啓動,預計將支持未來的增長。

  • 兩個中東市場的合規問題以及營養業務的自願產品召回立即得到解決。

  • 該公司計劃繼續投資於產品質量、品牌建設並持續執行其戰略。

  • 該公司強調了對股息增長的承諾,預計將繼續採取股票回購行動。

  • 2024年的增長計劃包括營養指數從高到中等的個位數下降,到年底恢復增長,資本支出區間增加到3-3.5%,淨收入同比增長2-4%。

  • 預計將在2024年實現強勁的自由現金流,從而爲股東帶來額外的回報。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論